leisure time -WSS

leisure time

author：hotspot 2025-10-01 12:22:26 - browse：1

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： U.S. death rates show how politics are affecting public health

explore

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

Why scientists need input from humanists on sensitive research

President Biden's budget: Here's what you might have missed

Change Healthcare outage fallout shows need for new oversight

As AI in medicine takes off, can 'human in the loop' prevent harm?

Medical students need to learn the potent medicine of empathy

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why we need mandatory labeling of GMO products

Dobbs anniversary: the lost opportunity of abortion as health care

How to save health care price transparency rules

United colonoscopy coverage change 'may cost lives,' doctors say

HHS secretary Becerra pressed on Change HealthCare cyberattack

In Memoriam: Notable people who died in 2023

First U.S. drug developed to treat liver disease MASH is approved

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Lawsuit challenges CMS nursing home minimum staffing rule

entertainment

EPA limits use of carcinogenic gas for sterilizing medical devices

Readout Newsletter: CAR

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Asahi Kasei to buy Calliditas, picking up kidney disease drug

First U.S. drug developed to treat liver disease MASH is approved

Boston's new lab space is opening empty

explore

entertainment

leisure time

hotspot